C Oliver Hanemann
Overview
Explore the profile of C Oliver Hanemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Laraba L, Hillson L, de Guibert J, Hewitt A, Jaques M, Tang T, et al.
Brain
. 2022 Sep;
146(4):1697-1713.
PMID: 36148553
Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2). There are no approved chemotherapies for these tumours and...
12.
Young C, Mills R, Langdon D, Sharrack B, Majeed T, Kalra S, et al.
J Neurol Sci
. 2022 Mar;
436:120188.
PMID: 35303502
Background: Longitudinal studies among people with Multiple Sclerosis (pwMS) have shown that self-efficacy is linked to physical, cognitive and psychological functioning. Objectives: To determine the distribution of self-efficacy in a...
13.
Maze E, Agit B, Reeves S, Hilton D, Parkinson D, Laraba L, et al.
Cancer Res
. 2021 Dec;
82(2):235-247.
PMID: 34853069
Deficiency of the tumor suppressor Merlin causes development of schwannoma, meningioma, and ependymoma tumors, which can occur spontaneously or in the hereditary disease neurofibromatosis type 2 (NF2). Merlin mutations are...
14.
Sofela A, McGavin L, Whitfield P, Hanemann C
Br J Neurosurg
. 2021 Jun;
35(6):696-702.
PMID: 34148477
Introduction: There are a number of prognostic markers (methylation, CDKN2A/B) described to be useful for the stratification of meningiomas. However, there are currently no clinically validated biomarkers for the preoperative...
15.
Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, et al.
Mol Cancer Ther
. 2021 Feb;
20(2):450.
PMID: 33547247
No abstract available.
16.
Sofela A, Hilton D, Ammoun S, Baiz D, Adams C, Ercolano E, et al.
Int J Mol Sci
. 2021 Jan;
22(2).
PMID: 33429944
There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum...
17.
Dunn J, Lenis V, Hilton D, Warta R, Herold-Mende C, Hanemann C, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33167358
Meningioma are the most frequent primary intracranial tumour. Management of aggressive meningioma is complex, and development of effective biomarkers or pharmacological interventions is hampered by an incomplete knowledge of molecular...
18.
Bracher M, Pilkington G, Hanemann C, Pilkington K
Front Bioeng Biotechnol
. 2020 Aug;
8:936.
PMID: 32850761
Background: A wide range of human methods have been developed and there is considerable interest in the potential of these studies to address questions related to clinical (human) use of...
19.
Negroni C, Hilton D, Ercolano E, Adams C, Kurian K, Baiz D, et al.
EBioMedicine
. 2020 Aug;
59:102941.
PMID: 32810829
Background: Meningiomas are the most common primary intracranial tumours. They are classified as grade I, II, and III based on their histopathological features. While most meningiomas can be managed by...
20.
Lyons Rimmer J, Ercolano E, Baiz D, Makhija M, Berger A, Sells T, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32629964
Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity...